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Antineutrophil cytoplasmic antibodies (ANCA) are the serological hallmark of some idiopathic systemic vasculitides. Besides the
investigation of ANCA-associated vasculitis (AAV) and constant effort for a standardized nomenclature and classification of the
AAV, a main focus of research during the last few years has been to constantly improve the performance of enzyme immunoassays.
With the latest so called third generation ELISA, this goal seemed to be fulfilled. The International Consensus Statement on
Testing and Reporting of ANCA gave recommendations for standardized strategies for the serological diagnosis of ANCA. New
developments now target the system immanent drawbacks of the respective diagnostic methods, be it the need for batching and the
long time to result for ELISA, or the high likelihood of error and subjectivity of indirect immunofluorescence (IIF). Random access
technology andmultiplexing for solid phase assays aswell as digital imaging for IIF are toolswhichmay help to expedite and simplify
routine diagnostics in the lab and in emergency settings. Recent findings indicate that PR3-ANCA have clinical utility beyond the
diagnosis of AAV. PR3-ANCA can also serve as an aid for the differentiation between ulcerative colitis (UC) and Crohn’s disease
(CrD) and the stratification of UC patients. This review provides a detailed review of what is known about ANCA and highlights
the latest research and state-of-the-art developments in this area.
1. Introduction
1.1. Historical Perspectives on Antineutrophil Cytoplasmic
Antibodies (ANCA). Antineutrophil cytoplasmic antibodies
(ANCA) are directed against primary granules of neutrophils
and are associated with neutrophil-mediated inflammation
[1]. ANCA were first described in 1982 by Davies et al. in
a series of patients with segmental necrotizing glomeru-
lonephritis (FNGN) and symptoms of systemic vasculitis [2].
In 1985 van der Woude et al. reported the strong associ-
ation of ANCA producing a diffuse granular cytoplasmic
staining pattern on ethanol-fixed neutrophils (C-ANCA) and
granulomatosis with polyangiitis (GPA) (formerly known
as Wegener’s granulomatosis (WG)) [3, 4]; a few years
later, ANCA producing a perinuclear fluorescent pattern
(P-ANCA) on the same cellular substrate were described
in patients with idiopathic necrotizing crescentic glomeru-
lonephritis and microscopic polyangiitis (MPA) [5]. Initially,
the only method available for ANCA detection was the
indirect immunofluorescence (IIF) test on normal human
ethanol-fixed neutrophils [3]. Although currently numerous
assay formats such as enzyme linked immunoassays (ELISA),
chemiluminescent immunoassays (CLIA), lateral flow assays
(LFA), and combinations of IIF and microbead assays have
beenmade available, the IIF still often remains the method of
choice for initial screening.
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1.2. Terminology and Molecular Biology of ANCA. The clas-
sical terms C-ANCA and P-ANCA describe IIF patterns on
granulocyte substrates [5–7]. C-ANCA (Figure 1(a)) is largely
due to the presence of autoantibodies targeting the serine
protease proteinase-3 (PR3), while P-ANCA (Figure 1(b))
is caused by antibodies directed mainly against myeloper-
oxidase (MPO). Additionally, antinuclear antibodies (ANA)
and antibodies against the cytoplasmic granule antigens
lactoferrin, lysozyme, azurocidin, elastase, cathepsin G,
bactericidal/permeability-increasing enzyme (BPI) show the
so-called atypical ANCA pattern on ethanol-fixed neu-
trophils [8–10]. MPO is the most frequently recognized
antigen in P-ANCA and primary systemic vasculitis [11]. PR3
is a weak cationic protein of 29-30 kDa molecular weight
(MW), belonging to the trypsin family of serine proteases.
PR3 is synthesized as a preproenzyme and subsequently
processed in four steps into the mature form. It is stored in
the azurophilic granules of neutrophils but can also be found
within themembrane of secretory vesicles. PR3 is physiologi-
cally inhibited by 𝛼1-antitrypsin [12]. MPO, which represents
about 5% of the total protein content of neutrophils, is a
strong cationic molecule (isoelectric point > 11) made up of a
heterodimer with a MW of ∼140 kDa. The enzyme is charac-
terized by a powerful bactericidal activity, whose peroxidase
activity is physiologically inhibited by ceruloplasmin [13].
1.3. Clinical Utility of ANCA. ANCA are the serological
hallmark of some idiopathic systemic vasculitides, and the
term ANCA-associated vasculitis (AAV) has been used to
collectively name those primary small vessel vasculitic syn-
dromes in which circulating ANCA are commonly found:
MPA and its renal limited form (pauci-immune necrotizing
glomerulonephritis), GPA, and eosinophilic granulomatosis
with polyangiitis (EGPA) [formerly known as Churg-Strauss
syndrome (CSS)] [14, 15]. This approach, adopted by the
International Chapel Hill Consensus Conference (CHCC)
and by the European Vasculitis Study Group (EUVAS), is
supported by the striking clinical and histological similarities
between the AAV, the widespread use of ANCA as a diagnos-
tic marker, and the growing evidence of their pathogenetic
potential [16]. An overview of the previous and the new
disease nomenclature as proposed by the 2012 CHCC for
defining small vessel vasculitis [15] is shown in Figure 2.
Apart from AAV, ANCA are also useful in the diagnosis
and classification of inflammatory bowel disease (IBD) [19,
20], autoimmune hepatitis (AIH), and primary sclerosing
cholangitis (PSC) [21]. Here, the IIF usually produces a perin-
uclear pattern,with homogeneous or fine speckled cytoplas-
mic fluorescence on ethanol-fixed slides [22]. The term atyp-
ical ANCA has been proposed to describe this pattern [23].
1.4. Pathogenicity of ANCA. Since 1995 in vitro, in vivo and
clinical studies have been providing increasing evidence in
favour of a pathogenetic role for ANCA (especially MPO-
ANCA) in the development of AAV. However, to induce
severe damage, ANCA have been shown to require addi-
tional triggers [24]. AAV are multifactorial diseases, and
the involvement of genetic factors in disease pathogenesis
is considered important as are environmental factors such
as silica exposure, infections (in particular with Staphylococ-
cus aureus) and treatment with propylthiouracil and other
drugs. Discovered by Kain et al. in 1995, autoantibodies
to LAMP-2, a suggested novel ANCA subtype, have been
reported to be present in almost all patients with active,
untreated AAV, and renal involvement [8, 25]. The authors
also suggested a previous unrecognized molecular expla-
nation for the origin and development of injury in pauci-
immune GN; however, such findings could so far not be
confirmed by a subsequent study [26]. Controversy exists
about the true prevalence, pathogenicity, and practical utility
of anti-LAMP-2-autoantibodies for the management of AAV
patients. Another new aspect of the pathology of ANCA
is the autoantibody stimulation by neutrophil extracellular
traps (NETs), also known as NETosis [27]. NETs are formed
from extracellular nuclear DNA of neutrophils released by
a programmed cell death different to apoptosis, releasing
strands of nuclear DNA spiked with antibacterial proteins
[28]. Bacteria, viruses, and fungi are trapped and killed in
theseNETs, and besides antimicrobial proteins PR3 andMPO
are present in the sticky DNA fibers [27–29]. Evidence of
NETosis as a possible trigger of AAV is evolving, as it was
shown that ANCA not only induce the neutrophil oxidative
burst but also can induce the programmed release of NETs in
absence of a microbial infection and, even more interesting,
that the transfer of activated myeloid dendritic cells enriched
withNET components into naivemice could cause AAV [30].
Also the ineffective clearance of NETs from the endothelial
vessel wall could give clue to the disease progression in AAV.
2. Diagnostic Methods for ANCA Detection
2.1. Overview. The sensitive and specific detection of anti-
bodies to PR3 and/or MPO is highly recommended in
patients with suspected systemic vasculitis, occurring in
about 80% of all AAV patients. Only fast and adequate
treatment can avoid the development of organ failure [31, 32].
In 1999, the International Consensus Statement on Testing
and Reporting of ANCAwas published, which provided sug-
gestions for ANCA testing and reporting [23]. An addendum
to this statement was published in 2003 with the quality con-
trol guidelines, comments, and recommendations for ANCA
testing in other autoimmune diseases [33]. According to these
guidelines, the initial screening method for ANCA is IIF on
ethanol-fixed neutrophils of human origin with confirmation
by a solid phase assay (i.e., ELISA). The specificity of the
individual tests (C-ANCA, P-ANCA, PR3, and MPO) is
not satisfactory; however, combining IIF and an ELISA for
PR3/MPO provides a specificity of 99% versus pathological
controls, with only a minor loss of sensitivity [34].
The identification and purification of the PR3 and MPO
antigens [5, 35, 36] allowed for the development of several
immunoassays for the quantitative detection of antibodies
specific for PR3 andMPO, including the conventional ELISA
and, more recently, line immunoassays (LIA) [37], capture
[38, 39], and anchor assays [40, 41] as well as multiplex assays
[42–44]. As ELISAs are only moderately fast with assay times
between 1.5 and 3 hours, the focus lately shifted towards
a decrease in assay time and fully automated technologies.
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Figure 1: Appearance of cytoplasmic indirect immunofluorescence pattern (C-ANCA, Figure 1(a)) and perinuclear (P-ANCA, Figure 1(b))
on ethanol-fixed human neutrophil cells. The C-ANCA pattern is largely caused by autoantibodies targeting serine protease proteinase-3
(PR3-ANCA), while the P-ANCA pattern is caused by antibodies binding to many antigens among which myeloperoxidase (MPO-ANCA) is
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Figure 2: Disease nomenclature system adopted by the 2012 International Chapel Hill Consensus Conference [17].
Lateral flow assays (LFA) reduce time to result and require
limited laboratory equipment. To reduce time to result and
minimize hands-on time in the laboratory, new systems com-
bining random access and chemiluminescent immunoassay
technology (CLIA) have been developed and offer single
patient testing together with assay times of as little as 30
minutes [45].
2.2. Indirect Immunofluorescence for ANCA Detection. The
International Consensus Statement on Testing and Reporting
of ANCA recommends that the minimum requirements for
ANCA testing are as follows: “IIF should be performed on
all sera from new patients, since 10% of ANCA positive sera
in patients with GPA or MPA can be demonstrated only by
IIF” [23, 33]. In spite of this, the strategy for the detection of
ANCA varies across laboratories, according to geographical
areas, traditions, and local experience. Additionally, the IIF
method in general, faces many challenges and occupies a
special and often not very popular place in the laboratory.
Historically both slide preparation and slide reading require
considerable manual work, are time consuming, and are
prone to technical problems in the hands of less experienced
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users [46–48]. Furthermore, the handwritten transcription
of results in the dark room is a hotbed of transcription
errors. High intra- and interlaboratory variability are also
observed in ANCA testing by IIF due to differences in
neutrophil sources, preparation, fixation, and subjectivity of
laboratory technologists. Unique to ANCA by IIF is the
recommendation for two different substrates (ethanol- and
formalin-fixed neutrophils) and the frequent presence of
cross-reactive ANA.
In recent years, automated fluorescent microscope sys-
tems that acquire, store, and display high resolution dig-
ital images obtained on IIF slides have been developed
(NOVA View, INOVA Diagnostics Inc. USA; Aklides, Medi-
pan GmbH, Germany; Image Navigator, Immuno Concepts
Ltd., USA; EURO-Pattern, Euroimmun AG, Germany). Dig-
ital images can be viewed and used any time for follow-
up, training, and consultation/second opinion purposes.
Software programs provide tools to support the operator’s
decision making such as negativity, positivity, and pattern
interpretation [46–50]. An important feature to increase the
accuracy of IIF interpretation is the possibility ofmultianalyte
screening and computerized display. Such systems candisplay
results of the same sample on different substrates (i.e., results
obtained on ethanol- and formalin-fixed substrates next to
results obtained on HEp-2 ANA; see Figure 3). However,
these programs should not be used to provide final results
as they require competent human confirmation for analysis
and reporting.This process does offer the benefits of reducing
hands-on time and transcription errors in addition to elimi-
nating the need for a dark room.
2.3. ELISA for ANCA Detection. After an initial IIF screen,
the results should be verified by ELISA [23] or an equivalent
solid phase assay. In the past, ELISA tests did not reach the
sensitivity and specificity of IIF on neutrophils [51, 52], but,
more recently, new methods offer improved results. These
methods utilize different immobilization strategies resulting
in presentation of the antigen in the most native way to
enable the best exposure of all relevant epitopes to the
antibody. Different immobilization techniques have led to
advancement in the generation of immunoassays aimed to
improve the sensitivity of the assays.
2.4. First Generation ELISA Tests. After the antigens targeted
by autoantibodies generating the P-ANCA and C-ANCA
pattern were described [5, 35, 36], the first ELISAs were
developed using purified native PR3 and MPO antigens.
These test kits used simple adsorption coating methods and
the purity of the antigens was quite variable [7]. Most tests
lacked comparability of results and correlation towards IIF
methods [51]. The limited sensitivity of these first generation
tests was attributed to the adsorption immobilization process
resulting inmasking and deformation of epitopes. In 1998, the
International Consensus Statement on Testing and Reporting
of ANCA by a proposed a combination of IIF and ELISA test
methods [23].
2.5. Second and Third Generation Tests. The low sensitivity
of the first generation ELISAs led to the development of
novel approaches to protein modification and different assay
methods. The so-called second generation ANCA tests used
capture molecules, mostly antibodies, to bind the antigens to
the surface without causing changes to the structure of the
epitopes [53]. These ELISAs showed a significant increase in
sensitivity and proved superior to the direct binding ANCA
tests [53].
Third generation assays, again, aimed to prevent the
antigen from being distorted, due to binding on the ELISA
plate, utilize “anchor” techniques to immobilize the antigens
[54]. The antigens are bound to the surface of the ELISA
plate using anchor molecules which are attached to the
surface of the ELISA plate. This method was discussed to
provide a better accessibility of epitopes and thus in a further
increase in the sensitivity and specificity as compared to IIF.
A comparative ROC analysis of three generations of PR3-
ANCA assays based on the detection of PR3-ANCA in the
sera of 86 GPA patients and 80 healthy control and 450
disease control sera revealed AUC values of 0.80 [95% CI:
0.76–0.83] (1st generation), 0.86 [95% CI: 0.82–0.89] (2nd
generation, capture ELISA), and 0.96 [95% CI: 0.94–0.98]
(3rd generation Anchor ELISA), respectively [54].
2.6. Other ELISA Methods. A novel approach using direct
coating in ELISA uses a mixture of a human native and
human recombinant PR3 antigen [55].Thismay offer a signif-
icantly higher sensitivity compared to first generation direct
coating and second generation capture methods; however
this has not been confirmed in all studies [56, 57].
2.7. Lateral Flow Assay Systems. Historically LFAs were
regarded as fast, but insensitive, reaching only about 80% of
the diagnostic performance of ELISAs [58–60]. Newer devel-
opments of LFAmade use of liquid antigens and significantly
improved the diagnostic performance of these tests. The use
of liquid antigens improves the antigen-antibody binding.
The antigens are added in solution, to minimize possible
masking of epitopes due to surface adhesion. Interpretation
of the test result can be done by a hand held reading
device and results can be interpreted semi-quantitatively.
Preliminary results indicate that this technology might reach
the sensitivity of ELISAs with an assay time of 20 minutes
[61, 62]. However, clinical use of LFA for the detection of
ANCA is extremely limited at most.
2.8. Combination of IIF and Bead Assays. A new approach
to combine screening for and confirmation of ANCA was
recently presented. This new technology combines ethanol-
fixed neutrophils and the antigens PR3, MPO, and GBM
coupled to different microbeads which are then attached
to different compartments of the IIF slide. The different
reactivities can be identified by either the size of the respective
bead or the position in different compartments of the IIF
slides. A first validation of this assay comparing the results
against a combination of IIF and ELISA results showed a
positive agreement in 124/129 (96.1%) samples and negative
agreement in 540/542 (99.6%) samples [63].
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Figure 3: Representative screenshot of a Multianalyte Screen (i.e., QUANTA Link, INOVA Diagnostics Inc.) showing a C-ANCA and
speckled ANA double positive sample. Images obtained on ethanol- and formalin-fixed substrates can be displayed next to Hep-2 ANA
results simultaneously and thus allow for interpretation with high accuracy.
Table 1: Agreement between a new PR3 CLIA assay and an established high sensitivity PR3 assay. Spearman’s rho of results was found at 0.74
(95% CI 0.67–0.80, data not shown) [65].
All patients (𝑛 = 196) ELIA PR3
s Percent agreement
(95% confidence)Positive Negative Total
PR3 CLIA
Positive 45 3 48 Pos. Agree = 86.5 (74.2–94.4%)
Negative 7 141 148 Neg. Agree = 97.9 (94.0–99.6%)
Total 52 144 196 Total Agree = 94.9 (90.8–97.5%)
2.9. Chemiluminescent Immunoassays for ANCA. Chemi-
luminescent assays (CLIA) are significantly different from
ELISA technology, as the antigen is covalently attached to
the surface of the bead particles unlike the passive adsorption
used for most ELISAs. Almost at the same time, two different
CLIA assays for the detection of PR3- and MPO-ANCA
have been developed on two systems: Zenit RA (A. Menarini
Diagnostica S.r.l., Florence, Italy) and BIO-FLASH (INOVA
Diagnostics Inc., SanDiego,USA). In the BIO-FLASH system
the epitope conformation of native PR3 and MPO antigens
and hence a reliable representation of epitopes have been
reported [40, 53]. In CLIA, paramagnetic beads are coupled
with native PR3 or MPO (Figure 4). After the beads are
incubatedwith diluted patient serum andwashed, antihuman
IgG isoluminol conjugate antibody “Tracer” is added. The
conjugate is oxidized when sodium hydroxide and peroxide
solutions “Triggers” are added and the flash of light produced
from this reaction is measured as relative light units (RLUs).
The RLUs are proportional to the amount of isoluminol
conjugate that is bound to the human IgG, which is in
turn proportional to the amount of autoantibodies bound
to the antigen on the beads. Unlike ELISA or addressable
laser bead immunoassays (ALBIA) platforms, the detection
system uses a proprietary CLIA technology that affords a
remarkably wider dynamic range, an entirely linear titration
curve, andmore consistent inter- and intratest reliability [64].
Recently the high sensitivity and specificity of a PR3CLIA, for
example, could be demonstrated in a large multicenter study
covering 11 laboratory sites in 9 different countries [65]. A
total of 1648 samples (292 GPA and 1356 disease controls)
were tested using a new PR3 CLIA assay (QUANTA Flash
PR3), which could discriminate GPA patient samples from
various disease controls with a ROC AUC value of 0.78 and
a specificity of 98.0% at a sensitivity of 62.7% (Figure 5).
In a smaller part of this multicenter study a comparison
against another assay revealed high percentages of agreement
between the new CLIA assay and another well-established
high sensitivity PR3 Assay (ELIA PR3s Thermo Scientific,
Germany) (Table 1). Both assays could discriminate between
samples fromGPApatients and controls with similar sensitiv-
ities and specificities: 56.1% (95%CI 44.7–67.0%)/98.2% (95%
CI 93.8–99.8%) sensitivity/specificity for QUANTA Flash,
and 58.5% (95% CI 47.1–69.3%)/96.5% (95% CI 91.3–99.4%)
sensitivity/specificity for ELIA PR3s. In another study 95
samples (20 P-ANCA positive by IIF versus 75 controls) were
tested with a newly developed MPO CLIA in comparison to
three different commercially available MPO-assays (Wieslab
MPO ANCA ELISA, Eurodiagnostica AB Sweden; Zenit RA
MPO ELISA, A. Menarini Diagnostica S.r.l., Florence, Italy;
and ELIA MPOs, Thermo Scientific, Germany). Both the
MPO CLIA and the Wieslab MPO-ANCA ELISA revealed
highest relative sensitivity/specificity compared to a positive
p-ANCA IIF result (Figure 6) reflected by AUC values of 0.97
(95% CI 0.92–1.00) for the Wieslab MPO-ANCA ELISA and
0.96 (95% CI 0.90–1.00) for the MPO CLIA [18].
2.10. Summary of Methods for ANCA Detection. Despite
several comparative studies, it remains debatable as to which
methodology for ANCA detection provides the highest clin-
ical accuracy for the diagnosis of SVV [53, 65, 66]. Several
6 Journal of Immunology Research
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Figure 4: Principle of QUANTA-Flash chemiluminescent immunoassays. Paramagnetic beads are coupled with native PR3 or MPO. The
beads are then incubated with diluted patient samples. After 9.5min incubation unbound antibodies are removed by washing. Antihuman
IgG isoluminol conjugate (Tracer) is added and binds immobilized antibodies. After another 9.5min incubation unbound Tracer is removed
by washing. Finally, Trigger 1 and Trigger 2 are injected and emerging light is measured. After injection of Trigger 1 and Trigger 2, the



































Sensitivity = 62.7% (95% CI 56.8–68.2%)
Specificity = 98.0% (95% CI 97.1–98.7%)
Cut-off = 20CU
False positive rate (1 − specificity)
n
n
Figure 5: Receiver operation characteristics (ROC) analysis of 292
GPA serum samples tested together with 1356 disease controls using
a novel PR3 CLIA revealed an area under the curve (AUC) value
of 0.78 (95% CI 0.74–0.83), resulting in a clinical sensitivity and
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Figure 6: Comparative receiver operation characteristics (ROC)
analysis of 20 P-ANCApositive serum samples tested by IIF together
with 75 disease and control serum samples using a novel MPO
CLIA and three other commercially available MPO assays revealed
AUC values of 0.97 (Wieslab MPO-ANCA), 0.96 (QUANTA Flash
MPO), 0.94 (Zenit RA MPO), and 0.94 (ELIA MPOs) resulting
in a relative sensitivity/specificity of 95%/96% (Wieslab MPO),
95%/96% (QUANTA Flash MPO), 86.7%/95.7% (Zenit RA MPO),
and 95%/94.7% (ELIA MPOs) against a positive P-ANCA result by
IFA, respectively [18].
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Figure 7: Differentiation between ulcerative colitis (UC) and Crohn’s disease (CrD).The clinical difference of UC and CrD and the potential
role of PR3-ANCA as a marker to help in the diagnosis of UC are illustrated.
studies published over the last decade suggested that the
sensitivity of both capture as well as novel anchor assays were
superior to classical ELISA and even to IIF [40, 41, 53, 67,
68]. Lately the new emerging technology of CLIA showed
comparable or superior sensitivity compared to established
assay types.
2.11. ANCA Testing in Emergency Setting. ANCA-associated
vasculitides are chronic multisystemic disorders, affecting
several organs, and characterized by the occurrence of flares
and remissions. Because of severe manifestations including
alveolar haemorrhage, rapid progressive glomerulonephritis,
scleritis, and necrotizing sinusitis, it is of the utmost impor-
tance to propose ANCA results in a timely manner [31, 32].
ANCA testing at presentation and in the case of suspected
disease flares should be requested urgently, in order to rapidly
initiate appropriate immunosuppressive therapies and avoid
irreversible organ damages [68, 69].
Relapses of the diseases occur in 30–60% of the patients
during 5–10 years of follow up and increase the risk of End
Stage Renal Disease (ESRD); therefore ANCA testing is also
required for the follow-up of the patients [70, 71]. According
to disease stage and activity, follow-up assessments include
ANCA testing at intervals of several months (three to six
months). Even if serial ANCA testing is controversial, ANCA
testing is usually ordered in case of suspicion of relapse,
side effect of immunosuppressive therapy or for differential
diagnosis with undercurrent infectious diseases [72, 73]. IIF
is inappropriate in the emergency setting due to its time
constraints and inability to quantify results.
Although controversially discussed, ANCA testing at
intervals is recommended as ANCA titresmay decline during
effective treatment and often rise prior to relapse [21, 74,
75]. In contrast to IIF, tests that give quantitative ANCA
measurements are required tomonitor disease activity. Lately
it was revealed that the use of native PR3 antigen together
with new assay technologies led to results correlating better to
the BirminghamVasculitis Activity Score (BVAS) than assays
using a combination of recombinant and native PR3 antigen
[45, 56].
Table 2: Prevalence of autoantibodies in ulcerative colitis and
Crohn’s disease [22, 77, 78, 82, 85].
Marker Ulcerative colitis Crohn’s disease
P-ANCA 40–60% 5–20%
ASCA IgG 5–10% 40–70%
ASCA IgA 5–10% 40–70%
PR3-ANCA 15–40% 0–10%
MZGP2 0–5% 20–40%
3. ANCA as Biomarkers in
Inflammatory Bowel Disease
Atypical P-ANCA is found in patients with inflammatory
bowel disease (IBD), mainly ulcerative colitis (UC) [76].
When combined with anti-Saccharomyces cerevisiae antibod-
ies (ASCA), atypical P-ANCA has been recommended as
a way to help distinguish UC from Crohn’s disease (CrD)
[22, 77–81]. ASCA seropositivity is a predominant feature of
CrD, while atypical P-ANCA is a marker of UC (Table 2)
[22, 78]. Both ASCA and ANCA have been reported to
predict the development of IBD [82]. Despite several studies,
the specificity of ANCA in IBD remains poorly defined
[77, 83]. The diagnosis of IBD including UC and CrD is
largely based on endoscopic and histological assessment of
the inflamed tissue [77, 84]. While several antibody tests can
assist in the diagnosis of CrD including ASCA and pancreatic
zymogen granule protein 2 (GP2) [85–87], the only sero-
logical biomarker for UC is atypical P-ANCA detected by
IIF [22]. However, IIF has the limitations described above
and is unable to provide information about ANCA antigen
specificity [77, 79]. Several studies have attempted to identify
the major target antigen of atypical P-ANCA in IBD [83, 88],
but major disease-specific target antigens are still missing.
In contrast to historical data [89, 90], more recent studies
reported PR3-ANCA in a significant percentage of IBD
patients [44]. This raises the possibility that akin to AAV,
PR3-ANCA may also be a marker for IBD. However, early
studies of PR3-ANCA in IBD have been based on relatively
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small cohorts of UC patients [44, 91, 92]. When twelve
PR3 ANCA assays were compared using 22 IBD sera, the
reported prevalence of PR3-ANCA ranged from 4% to 43%,
raising concerns as to the reliability of the assays used in
these studies [44, 91–93]. The two assays with the highest
sensitivity [BINDAZYME (Binding Site Ltd.) sensitivity: 39%
and Rainbow ELISA PR3 (Bio-diagnostics Ltd.) sensitivity:
43%] also showed the lowest specificity (88%) [44].
Recently it was suggested that PR3-ANCAmeasured by a
novel chemiluminescent immunoassay (CLIA) on a random
access autoanalyzer (BIO-FLASH) are useful in the differen-
tial diagnosis of UC and CrD [19]. Our observation that PR3-
ANCA can be detected in sera from patients with IBD, with
higher prevalence in UC versus CrD patients suggests that
PR3-ANCA testing could assist in discriminating UC from
CrD and in discriminating IBD from other gastrointestinal
conditions.The terms “indeterminate colitis” or “IBD unclas-
sified” (IBD-U) categorize patients in whom the diagnosis
of UC or CrD is not clear [77, 94, 95]. The differential
diagnosis may be complicated in patients with irritable bowel
syndrome, celiac disease, or other gastrointestinal diseases
with symptoms indistinguishable from those seen in IBD
[77]. Furthermore, our data pointed to a possible role as
biomarker for a lesser need of immunomodulatory therapy in
UCpatientswith PR3-ANCA [19], although these data should
be confirmed in further studies.
3.1. Differentiation between PR3-ANCA Positive UC and GPA
Patients. The fact that PR3-ANCA is found in UC could be
interpreted as compromising the specificity of PR3-ANCA
for GPA. However, PR3-ANCA in patients with GPA are
often associated with a C-ANCA pattern on ethanol-fixed
neutrophils, while in UC patients an atypical P-ANCA is
most often observed. The latter is most likely explained by
reactivity to other antigens that have been reported in the past
to be associated with UC [20]; see Figure 7. Consequently,
differential diagnosis of GPA and UC in PR3-ANCA positive
individuals can be achieved using the clinical presentation of
the patient and the combination of PR3-ANCA and IIF.
Interestingly recent studies have described patients with
overlapping features of UC and GPA [96–98]. To what
extent PR3-ANCA positive UC patients will develop full-
blown AAV over the course of their disease needs to be
assessed in large longitudinal studies. It is widely appreciated
that different autoimmune diseases can overlap in certain
patients, which was recently described as polyautoimmunity
[99]. Therefore, additional studies are required to deter-
mine whether there is an overlap between the two chronic
inflammatory diseases.While GPA typically affects the upper
respiratory tract and the kidneys, UC is limited to the
colon. Although, 10% of patients with SVV, can present with
ulcerations of the colon [100], isolated gastrointestinal tract
involvement is infrequently seen in ANCA-positive patients
with SVV [101].
4. Conclusion
The names of the common forms of vasculitis have been
recently revised so that the eponyms such as WG and
CSS have been changed to GPA and EGPA, respectively.
ANCA testing by IIF remains an important first step when
screening for ANCA. Positive results, or cases of strong
clinical suspicion should be run on a solid phase assay for
confirmation of the antigenic specificity and quantitation of
the results. Automated solutions for autoimmune laboratories
performing IIF assays simplify and streamline the IIF read-
ing/interpretation workflow and increase the reliability of IIF
testing by sample traceability. Despite big improvements in
sensitivity and specificity, ELISAmethods often are burdened
with batching and relatively long result times. Acute disease
flares can be confounding, so accurate, rapid diagnosis
followed by appropriate therapy is paramount to halting the
deleterious effects of ANCA vasculitic disease, especially in
an emergency setting. Not all PR3 assays are suited for disease
activity monitoring. PR3-ANCA are present in a significant
percentage of IBD patients and may be a marker of concur-
rent SVV related disease. PR3-ANCA measured by CLIA are
promising to aid in the differential diagnosis of UC and CrD.
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